[ad_1]
The president of Brazil, Jair Bolsonaro, commented on Tuesday in a victory tone the suspension of tests of Coronavac, a Chinese vaccine under test against Covid-19, determined by the National Health Surveillance Agency (Anvisa) after the death of a volunteer. in the country.
“Another victory for Jair Bolsonaro,” the president wrote on his Facebook account in response to a follower who asked him if the government would buy the vaccine developed by the Chinese laboratory Sinovac, currently in the final testing phase, if its effectiveness is proven. .
Coronavac is being tested in Brazil through a partnership between Sinovac and the São Paulo state authorities, whose governor, João Doria, became one of Bolsonaro’s fiercest opponents in the conservative field. “Death, disability, anomaly. This is the vaccine that Doria wanted to force the people of São Paulo to take, “added the Brazilian president in the same message, in which he reiterated that immunization” could never be mandatory “in Brazil, as the São Paulo governor defends.
In the past month, Bolsonaro had already said that “the Brazilian people will not be a guinea pig to anyone” and that “there is no justification for an economic contribution of one billion dollars in a drug that has not even passed the testing phase”, alluding to what he had already said about the “Doria vaccine” and that, he warned, “no it will be bought ”by your Government.
A suspension The Coronavac tests in Brazil were announced Monday by Anvisa, the official regulatory body, after being notified of the occurrence of a “serious adverse event”. In a note, Anvisa explained that “it decided to interrupt the study to evaluate the data observed so far and judge the risk / benefit of continuity” after being informed about this “serious adverse event” on October 29.
The Butantan Institute, a laboratory associated with the São Paulo regional government that commands the Coronavac tests, stated that the death of one of the study volunteers “is not related to the vaccine” and, therefore, considered that the tests should continue. Along the same lines, argued the Chinese pharmaceutical company, which in a note released in Beijing was convinced of the “safety” of its vaccine.
“The clinical study in Brazil is being carried out rigorously and in accordance with the requirements of good clinical practice, and we are convinced of the safety of the vaccine, “Sinovac said in a brief statement posted on its website. “After communicating with our Brazilian partner, Instituto Butantan, we learned that their management believes that this serious adverse event has nothing to do with the vaccine,” he said. The heads of Anvisa and Instituto Butantan have scheduled a meeting for this Tuesday to clarify the matter and decide on the possible resumption of the experience or the maintenance of the suspension, in case there are still doubts.
Brazil is the Portuguese-speaking country most affected by the pandemic and one of the most affected in the world, accounting for the second number of deaths (more than 5.6 million cases and 162,628 deaths), after the United States. The Covid-19 pandemic caused at least 1,263,890 deaths in more than 50.9 million cases of infection worldwide, according to a report by the French agency AFP.
